Method for analyzing action mechanism of compound for treating breast cancer based on network pharmacology and molecular docking

Through network pharmacology and molecular docking analysis, the research process of breast cancer treatment was simplified, the mechanism of action of hexachlorophen on breast cancer was understood, and the rapid prediction and effective treatment of breast cancer was achieved, and the efficacy of the existing technology was solved. Good question.

CN119091953APending Publication Date: 2024-12-06CHONGQING MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410913251.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-09
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing breast cancer treatments are not effective, and online pharmacological methods are complex and difficult to learn, making it a lot of time and resources to understand the mechanism of action of compounds in treating breast cancer.

Method used

Using a method based on network pharmacology and molecular docking analysis, a protein interaction network was constructed through databases such as PubChem, SwissTargetPrediction, Uniprot, GeneCards, STRING, Cytoscape, Metascape, etc., to carry out KEGG pathway enrichment analysis and GO functional enrichment analysis, combining molecules Docking technology explores the mechanism of action of hexachlorophen on breast cancer.

Benefits of technology

Simplifies the learning process of online pharmacology, quickly understands the targets and signaling pathways of compounds and breast cancer-related proteins, provides detailed simulations of hexachlorophenol and specific target proteins of breast cancer, revealing its precise molecular interactions in the treatment of breast cancer, It reduces the time and resources for preclinical research and promotes the clinical application of effective therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure HDA0004934303290000011
    Figure HDA0004934303290000011
  • Figure HDA0004934303290000012
    Figure HDA0004934303290000012
Patent Text Reader

Abstract

The invention discloses a method for analyzing an action mechanism of a compound for treating breast cancer based on network pharmacology and molecular docking. The method comprises the following steps: S1, acquiring a drug-disease common target; s2, constructing a protein mutual (PPI) network; s3, acquiring a core target spot; s4, carrying out KEGG pathway enrichment analysis and GO function enrichment analysis to explore a specific mechanism; and S5, further exploring the mechanism through molecular docking. According to the method, the enrollment threshold of network pharmacology is simplified, the data is directly mined in each database, and the network pharmacology is combined with molecular docking, so that the content is more layered, and the action mechanism of the compound for treating the breast cancer can be accurately analyzed.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a pharmacological mechanism research method, and in particular to a method for analyzing the mechanism of action of a compound in treating breast cancer based on network pharmacology and molecular docking. Background Art

[0002] The conventional treatment for breast cancer is surgical resection and chemotherapy, but the efficacy is poor and the prognosis is poor. Therefore, it is urgent to find new and effective drugs to improve the survival rate of breast cancer patients.

[0003] Hexachlorophene (HCP) is an effective antibacterial drug that has bactericidal effects on a variety of Gram-positive bacteria, including Staphylococcus, Streptococcus, and Pneumococcus. HCP also has anti-tumor properties. Through drug screening and molecular docking, it was found that HCP can reduce the expression and phosphorylation of Src homology 2 domain-containing protein tyrosine phosphatase-2 (SHP2), and inhibit the proliferation and migration of KRAS-mutated non-small cell lung cancer cells by inhibiting the RAS / MEK / ERK and PI3K / AKT signaling pathways; HCP can act as an inhibitor of glucose-regulated protein 78 (GRP78), leading to apoptosis of colon cancer cells by inducing autophagy; in addition, HCP can inhibit the expression of cyclin D1, a β-catenin target gene, thereby inhibiting the growth of colon cancer cells. Researchers have found that HCP has an inhibitory effect on breast cancer, but the mechanism of action of HCP on breast cancer has not been clearly studied.

[0004] Network pharmacology and molecular docking are important tools for understanding the molecular targets and mechanisms of action of compounds for treating diseases. However, current network pharmacology methods generally require learning R language in advance. The complex code and easy error reporting of R language discourage most beginners. In addition, learning network pharmacology requires access to multiple databases, and the gene naming methods of different databases are different, which require database conversion. Therefore, it takes a lot of time to explore and learn, and it is necessary to flexibly adjust according to one's own research content. Summary of the invention

[0005] The purpose of the present invention is to solve the above problems and provide a method for analyzing the mechanism of action of compounds in treating breast cancer based on network pharmacology and molecular docking, comprising the following steps:

[0006] S1: Acquisition of drug-disease common targets

[0007] The 2D or 3D structure of the compound is obtained from the PubChem database, and the target of the compound is predicted. The 2D structure of the compound is then used to search in the SwissTargetPrediction database, and the target of the compound is screened with Probability>0 to obtain the target of the compound again. The Uniprot database is used to find the corresponding Uniprot ID according to the gene name of the obtained compound target. The GeneCards database is searched with "Breast cancer" as the keyword to predict the target of breast cancer, and the target is screened with Score≥5. The breast cancer and drug targets obtained by the above method are used to draw a Venn diagram through DrawVennDiagram to obtain the potential target of the compound for intervening in breast cancer.

[0008] S2: Protein-protein interaction (PPI) network construction

[0009] The obtained compound-breast cancer common targets were imported into the STRING database to establish a PPI network, the protein classification was set to "Homo sapiens", the interaction score was >0.4, the other parameters of the PPI network were set to default, free targets were removed, a PPI network diagram was established, and a PPI network relationship table was obtained;

[0010] S3: Acquisition of core targets

[0011] The obtained PPI network relationship table was imported into Cytoscape3.9.1 to create the PPI network relationship of compounds for potential targets for intervention in breast cancer, and the cytoHubba plug-in was used to calculate the Betweenness, Closeness, and Degree values ​​to screen out the core targets;

[0012] S4: KEGG pathway enrichment analysis and GO function enrichment analysis to explore its specific mechanism

[0013] The Metascape database was used to perform KEGG pathway enrichment analysis and GO functional enrichment analysis on the potential targets of the compounds in breast cancer. The KEGG pathway enrichment analysis and GO functional enrichment analysis obtained from the Metascape database were sorted according to -log10(P) (preferably in descending order). The potential mechanism of the compounds acting on breast cancer was obtained through KEGG pathway enrichment analysis and GO functional enrichment analysis;

[0014] S5: Molecular docking to further explore its mechanism

[0015] The KEGG pathway enrichment analysis revealed a signaling pathway that was closely related to the compound's mechanism of action on breast cancer. Based on the core targets of the compounds acting on breast cancer obtained by S3, molecular docking was performed between the compounds and the core targets, and it was concluded that this core target played a vital role in the compound's action on breast cancer.

[0016] Preferably, in step S2, if the constructed PPI network diagram has a complex relationship structure, the minimum required interaction score is set to "high confidence" to further optimize the network diagram, and the remaining settings are the same to obtain the node degree of the relevant target gene. The larger the node, the larger the degree value, indicating that the protein has a better correlation with the therapeutic mechanism, and the target gene closely related to the therapeutic mechanism of the compound for breast cancer is obtained. Then, the obtained PPI network relationship table is imported into Cytoscape3.9.1, and the core targets are obtained using the cytoHubba plug-in, thereby obtaining the core targets of the compound acting on breast cancer.

[0017] Preferably, in step S2, the minimum required interaction score is "medium confidence", that is, the score value is greater than 0.4.

[0018] Preferably, in step S3, the cytoHubba plug-in is used to calculate the Betweenness, Closeness and Degree values ​​respectively, and the important target genes are obtained according to the top ten rankings. A Venn diagram is drawn by Draw Venn Diagram to obtain the core targets of the compound intervention in breast cancer.

[0019] Preferably, in step S4, the KEGG pathway enrichment analysis and GO functional enrichment analysis obtained by the Metascape database are sorted in descending order according to -log(10) (P-value<0.01), and the Metascape database directly visualizes the results of the KEGG pathway enrichment analysis and GO functional enrichment analysis.

[0020] Preferably, in step S5, the molecular docking obtains the receptor protein for docking through the PDB database; obtains the ligand molecule for docking through the PubChem database, and uses the CB-DOCK2 database for molecular docking; the CB-DOCK2 database directly visualizes the ligand-receptor molecule docking.

[0021] Preferably, the compound is hexachlorophene.

[0022] The beneficial effects of the present invention are:

[0023] (1) The present invention is an improvement on the conventional method of network pharmacology. It mainly screens through various databases. Unlike the conventional network pharmacology method, it is not necessary to learn computer languages ​​such as R language, which simplifies the learning of network pharmacology. In addition, the method used in the present invention is to directly mine data in various databases, which is convenient for better understanding the functions of each database, and combines network pharmacology with molecular docking to make the results more accurate, and analyzes in detail the mechanism of action of hexachlorophene on breast cancer.

[0024] (2) Network pharmacology can explore the interaction between hexachlorophene and breast cancer-related protein targets or pathways, thereby gaining a more comprehensive understanding of the mechanism of action of hexachlorophene in breast cancer. Through network pharmacology, the core protein targets of hexachlorophene that play a key role in breast cancer are identified. In addition, molecular docking can provide a detailed simulation of the interaction between hexachlorophene and specific target proteins of breast cancer by computer prediction of the sites where proteins bind to small molecule compounds. This computer simulation-based technology enables researchers to explore the three-dimensional structure of drug-target sites and evaluate the binding affinity of hexachlorophene to their respective targets. Therefore, the precise molecular interactions behind hexachlorophene's treatment of breast cancer can be revealed through the above methods. These methods help researchers make rapid predictions based on the interaction between specific compounds and target proteins and their potential efficacy in breast cancer treatment, reducing the time and resources required for preclinical research and ultimately bringing effective breast cancer therapies closer to clinical application.

[0025] (3) This invention proposes for the first time the specific mechanism of action of hexachlorophene in inhibiting breast cancer. Combining network pharmacology with molecular docking helps researchers explore the potential mechanism of compounds in treating breast cancer based on the interaction between specific compounds and target proteins. This method greatly simplifies the drug development process and saves researchers' time. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 are the 2D and 3D chemical structures of hexachlorophene.

[0027] Figure 2 The targets of hexachlorophene were obtained through the PubChem and SwissTargetPrediction databases, and then converted through the Uniprot database to obtain the targets of hexachlorophene. The targets of breast cancer were obtained from the GeneCards database and screened according to "Relevance score ≥ 5", and the Venn diagram was drawn through Draw VennDiagram.

[0028] Figure 3 It is a protein-protein interaction (PPI) network diagram.

[0029] Figure 4This is the protein interaction (PPI) network diagram processed by Cytoscape3.9.1.

[0030] Figure 5 Cytoscape3.9.1 and its plug-in cytoHubba are used to screen key target maps. Figure A: Calculate the value of Betweenness and screen out the top ten genes. Figure B: Calculate the value of Closeness and screen out the top ten genes. Figure C: Calculate the value of Degree and screen out the top ten genes. Figure D: Draw a Venn diagram.

[0031] Figure 6 It is KEGG pathway enrichment analysis and GO functional enrichment analysis, Figure A: KEGG pathway enrichment analysis, Figure B: GO functional enrichment analysis biological process (BP), C: GO functional enrichment analysis cellular component (CC), D: GO functional enrichment analysis molecular function (MF).

[0032] Figure 7 It is the expression of core genes in normal breast tissue and breast cancer tissue.

[0033] Figure 8 It is the impact of core genes on breast cancer prognosis.

[0034] Fig. 9 The core genes were molecularly docked with hexachlorophenol. Figure A: molecular docking analysis of AR with hexachlorophenol, Figure B: molecular docking analysis of ESR1 with hexachlorophenol, Figure C: molecular docking analysis of CTNNB1 with hexachlorophenol, Figure D: molecular docking analysis of PTGS2 with hexachlorophenol, Figure E: molecular docking analysis of TP53 with hexachlorophenol, Figure F: molecular docking analysis of MYC with hexachlorophenol, Figure G: molecular docking analysis of EGFR with hexachlorophenol. DETAILED DESCRIPTION

[0035] The present invention will be further described below in conjunction with embodiments, but the present invention is not limited thereto.

[0036] The experimental methods in the following examples are conventional methods unless otherwise specified.

[0037] Example 1

[0038] The method of the present invention for analyzing the mechanism of action of hexachlorophene in treating breast cancer based on network pharmacology and molecular docking is operated according to the following steps:

[0039] S1: Acquisition of drug-disease common targets

[0040] The PubChem (https: / / pubchem.ncbi.nlm.nih.gov / ) database was used to search for “Hexachlorophene” as the keyword to predict the targets of hexachlorophene, and 48 targets were obtained. The 2D structure and 3D compound structure of hexachlorophene were also obtained ( Figure 1 ), the SwissTargetPrediction (http: / / swisstargetprediction.ch / ) database was searched according to the 2D structure obtained by PubChem, and Probability>0 was used for screening to obtain 37 targets. After deleting 5 duplicate values, 80 targets were obtained. The Uniprot (https: / / www.uniprot.org / ) database was used to identify 1070 active targets of hexachlorophene from the obtained compound targets. The GeneCards (https: / / www.genecards.org / ) database was searched with "Breast cancer" as the keyword to predict the targets of breast cancer, and "Score≥5" was used for screening to obtain 4106 targets of breast cancer. The breast cancer targets and hexachlorophene targets were obtained by the above method, and a Venn diagram was drawn by Draw Venn Diagram (https: / / bioinformatics.psb.ugent.be / webtools / Venn / ) to determine the common targets of hexachlorophene and breast cancer. The Venn diagram results showed that there were 50 potential targets, and the potential targets of hexachlorophene for intervention of breast cancer were obtained ( Figure 2 ).

[0041] S2: Protein-protein interaction (PPI) network construction

[0042] The obtained hexachlorophenol-breast cancer common targets were imported into the STRING (https: / / cn.string-db.org / ) database to check whether there were protein interactions between the 50 potential targets screened out. The protein classification was set to "Homosapiens" and the minimum required interaction score was "medium confidence (0.4)". The other parameters of the PPI network were obtained according to the default settings. Free targets were removed and the PPI network diagram was established. The constructed PPI network includes 47 nodes and 285 edges, with an average node degree of 11.4 and a PPI enrichment p value of less than 1.0e-16 ( Figure 3). Then the obtained PPI network relationship table was imported into Cytoscape3.9.1 (https: / / www.cytoscape.org / ). The larger the node, the greater the degree value, indicating that the protein has a better correlation with the treatment mechanism. Finally, it was concluded that target genes such as ESR1, TP53, CTNNB1, PTGS2, EGFR, AR, BCL2, and MAPK3 are closely related to the molecular mechanism of hexachlorophene in the treatment of breast cancer ( Figure 4 ).

[0043] S3: Acquisition of core targets

[0044] The obtained PPI network relationship table was imported into Cytoscape3.9.1 (https: / / www.cytoscape.org / ), and the Betweenness, Closeness, and Degree values ​​were calculated using the cytoHubba plug-in. The top ten targets in terms of Betweenness, Closeness, and Degree values ​​were selected to obtain key targets, and the Venn diagram was drawn using Draw Venn Diagram (https: / / bioinformatics.psb.ugent.be / webtools / Venn / ). Figure 5 ), it was concluded that AR, ESR1, CTNNB1, PTGS2, TP53, MYC, and EGFR are the core targets of hexachlorophene in breast cancer, suggesting that these target genes are important in the therapeutic mechanism of hexachlorophene for breast cancer.

[0045] S4: KEGG pathway enrichment analysis and GO function enrichment analysis to explore its specific mechanism

[0046] The Metascape database (https: / / metascape.org / ) was used to perform KEGG pathway enrichment analysis and GO functional enrichment analysis on the common potential targets of hexachlorophenol and breast cancer, to further explore the potential mechanism of hexachlorophenol in breast cancer and determine its biological characteristics. The Metascape database can directly obtain the visualization results of KEGG pathway enrichment analysis ( Figure 6), sorted in descending order by -log10(P), and KEGG pathway enrichment analysis showed that there were 14 signaling pathways for hexachlorophene to act on breast cancer (P-value<0.01, statistically significant), which were mainly related to cancer pathways, signaling pathways regulating stem cell pluripotency, serotonin pathways, platinum drug resistance pathways, Hippo signaling pathways, chemical carcinogenesis pathways, p53 signaling pathways and other signaling pathways. The biological process (BP), cellular component (CC) and molecular function (MF) were obtained through the Metascape database and sorted in descending order by -log10(P). The GO analysis data (including BP, CC, MF) were displayed according to the Metascape database ( Figure 6 ). GO functional enrichment analysis showed that the common targets of hexachlorophenol and breast cancer were involved in a series of biological processes, including the response to xenobiotic stimulation, unsaturated fatty acid metabolism, the regulation of apoptosis signaling pathways, cell proliferation, etc.; in cellular components, the common targets of hexachlorophenol and breast cancer mainly targeted membrane rafts, vesicle cavities, transcriptional repressor protein complexes, glutamatergic synapses, nuclear envelope, etc.; in molecular functions, the common targets of hexachlorophenol and breast cancer were mainly involved in phosphatase binding, oxidoreductase activity, intramolecular oxidoreductase activity, transcription factor binding, protein kinase activity, etc.

[0047] S5: Exploring the expression of core genes in normal breast tissue and breast cancer and their impact on prognosis

[0048] Based on the 7 key targets of hexachlorophene on breast cancer obtained above, UALCAN (https: / / ualcan.path.uab.edu / ) was used to obtain the expression of 7 core genes, AR, ESR1, CTNNB1, PTGS2, TP53, MYC, and EGFR, in normal breast tissue and breast cancer tissue. In the patients with invasive breast cancer in the UALCAN TCGA database, the mRNA levels of AR, ESR1, CTNNB1, PTGS2, TP53, MYC, and EGFR in normal tissue and tumor tissue were significantly different ( Figure 7 ). Kaplan-Meier Plotter (https: / / kmplot.com / ) was used to obtain the effects of 7 core genes on prognosis in breast cancer. The results showed that recurrence free survival (RFS) was related to AR, ESR1, CTNNB1, PTGS2, TP53, MYC, and EGFR ( Figure 8 ).

[0049] S6: Molecular docking to further explore its mechanism

[0050] According to the seven core targets of hexachlorophene acting on breast cancer, namely AR, ESR1, CTNNB1, PTGS2, TP53, MYC, and EGFR, which are closely related to the therapeutic mechanism of hexachlorophene on breast cancer, molecular docking of hexachlorophene with the seven core targets, namely AR, ESR1, CTNNB1, PTGS2, TP53, MYC, and EGFR, was performed ( Fig. 9 ), in this docking, the receptor protein for docking was obtained through the PDB website (https: / / www.rcsb.org / ), the 3D structure of hexachlorophene was obtained through PubChem (https: / / pubchem.ncbi.nlm.nih.gov / ), and the blind docking tool CB-DOCK2 website (https: / / cadd.labshare.cn / cb-dock2 / php / index.php) was used for molecular docking, which focused on improving docking accuracy. CB-DOCK2 predicted the binding region of a given protein, and the curvature-based cavity detection method calculated the center and size. The docking was performed by the currently popular docking program AutodockVina, and the parameters were set to the default settings. Table 1 shows the PDB ID and Vina Score corresponding to the seven core targets of AR, ESR1, CTNNB1, PTGS2, TP53, MYC, and EGFR.

[0051] from Fig. 9 We can see that the ligand is deeply buried in the binding cavity of the protein, and the results in Table 1 show that hexachlorophene has a strong binding ability with the seven core targets of AR, ESR1, CTNNB1, PTGS2, TP53, MYC, and EGFR. In summary, the molecular docking results are consistent with the screening results based on network pharmacology, indicating that the network pharmacology tool is effective in this study.

[0052] Table 1 Scoring of molecular docking between core genes and hexachlorophene

[0053]

[0054] In summary, the present invention provides a method for analyzing the mechanism of action of hexachlorophenol in treating breast cancer based on network pharmacology and molecular docking. The analysis found that hexachlorophenol plays an important role in the treatment of breast cancer by affecting seven core targets, namely AR, ESR1, CTNNB1, PTGS2, TP53, MYC, and EGFR. GO functional enrichment analysis suggests that hexachlorophenol-breast cancer potential targets are mainly involved in a series of biological processes such as cell proliferation and apoptosis; KEGG pathway enrichment analysis suggests that the mechanism of hexachlorophenol acting on breast cancer is closely related to the Hippo signaling pathway and the p53 signaling pathway. In summary, our network pharmacology analysis and molecular docking research results provide an important basis for further research.

Claims

1. A method for analyzing the mechanism of action of a compound in treating breast cancer based on network pharmacology and molecular docking, comprising the following steps: S1: Acquisition of drug-disease common targets The 2D or 3D structure of the compound is obtained from the PubChem database, and the target of the compound is predicted. The 2D structure of the compound is then searched in the SwissTargetPrediction database, and the target of the compound is obtained again by screening with Probability>0; Use the Uniprot database to find the corresponding Uniprot ID of the acquired compound targets according to the gene name; The GeneCards database was searched with "Breast cancer" as the keyword to predict the action targets of breast cancer, and the screening was performed with Score ≥ 5; the breast cancer and drug targets obtained by the above method were used to draw a Venn diagram through Draw Venn Diagram to obtain the potential targets of compound intervention in breast cancer; S2: Protein-protein interaction (PPI) network construction The obtained compound-breast cancer common targets were imported into the STRING database to establish a PPI network, the protein classification was set to "Homo sapiens", the interaction score was >0.4, the other parameters of the PPI network were set to default, free targets were removed, a PPI network diagram was established, and a PPI network relationship table was obtained; S3: Acquisition of core targets The obtained PPI network relationship table was imported into Cytoscape3.9.1 to create the PPI network relationship of the compound intervention potential targets for breast cancer, and the cytoHubba plug-in was used to calculate the Betweenness, Closeness, and Degree values ​​to screen out the core targets; S4: KEGG pathway enrichment analysis and GO function enrichment analysis to explore its specific mechanism Metascape database was used to perform KEGG pathway enrichment analysis and GO functional enrichment analysis on potential targets of compounds in breast cancer. KEGG pathway enrichment analysis and GO functional enrichment analysis obtained from Metascape database were sorted according to -log10(P). The potential mechanism of compounds acting on breast cancer was obtained through KEGG pathway enrichment analysis and GO functional enrichment analysis. S5: Molecular docking to further explore its mechanism The KEGG pathway enrichment analysis revealed a signaling pathway that was closely related to the compound's mechanism of action on breast cancer. Based on the core targets of the compounds acting on breast cancer obtained by S3, molecular docking was performed between the compounds and the core targets, and it was concluded that the core targets played a vital role in the compound's action on breast cancer.

2. The method according to claim 1, characterized in that: In the step S2, if the constructed PPI network diagram has a complex relationship structure, the minimum required interaction score is set to "high confidence" to further optimize the network diagram, and the remaining settings are the same to obtain the node degree of the relevant target gene. The larger the node, the larger the degree value, indicating that the protein has a better correlation with the therapeutic mechanism, and the target gene closely related to the therapeutic mechanism of the compound for breast cancer is obtained. Then, the obtained PPI network relationship table is imported into Cytoscape3.9.1, and the core targets are obtained using the cytoHubba plug-in, thereby obtaining the core targets of the compound acting on breast cancer.

3. The method according to claim 1, characterized in that: In step S2, the minimum required interaction score is "medium confidence", that is, the score value is greater than 0.

4.

4. The method according to claim 1, characterized in that: In step S3, the cytoHubba plug-in is used to calculate the Betweenness, Closeness, and Degree values, respectively, and the important target genes are obtained according to the top ten rankings. A Venn diagram is drawn by Draw VennDiagram to obtain the core targets of the compounds for intervening in breast cancer.

5. The method according to claim 1, characterized in that: In step S4, the KEGG pathway enrichment analysis and GO functional enrichment analysis obtained from the Metascape database are sorted in descending order according to -log10(P) (P-value<0.01), and the Metascape database directly visualizes the results of the KEGG pathway enrichment analysis and GO functional enrichment analysis.

6. The method according to claim 1, characterized in that: In the step S5, the receptor protein for docking is obtained through the PDB database for molecular docking; the ligand molecule for docking is obtained through the PubChem database, and the molecular docking is performed using the CB-DOCK2 database; The CB-DOCK2 database directly visualizes ligand-receptor molecular docking.

7. The method according to claim 1, characterized in that: The compound is hexachlorophene.